Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

In a major international trial, researchers from McMaster University in Canada, found that the hypertension drug irbesartan reduced the risk of heart failure complications and the combination of stroke, other embolic events and transient ischemic events, also known as ministrokes, in patients with atrial fibrillation.

2 Sep 2009

Patient enrollment completed for the Berlin Heart EXCOR Pediatric IDE clinical study

Berlin Heart Inc. reported today that it has completed enrollment in Cohort 1 of the Berlin Heart EXCOR(R) Pediatric IDE Study after having received unconditional approval of the study from the FDA in November 2008.

2 Sep 2009

First AbioCor Total Replacement Heart recipient does not survive

Abiomed, Inc. (NASDAQ: ABMD), has been informed by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital, that the first patient to receive the commercial AbioCor Total Replacement Heart, died on August 23, 2009, due to post-operative conditions unrelated to the device.

1 Sep 2009

Telemonitoring systems enable early detection of silent, asymptomatic arrhythmias in heart

An increasing number of heart failure patients are treated with a number of complex devices, i.e. cardiac resynchronization therapy (CRT). Recently completed and ongoing clinical trials such as MADIT-CRT and EchoCRT provide evidence of a growing number of CRT patients, in need of individualised treatment.

1 Sep 2009

Atrial fibrillation ablation - one of the fastest growing cardiology techniques

Atrial fibrillation ablation is one of the fastest growing techniques in cardiology and due to the very high number of patients that might be candidates to this procedure, a significant number of resources will have to be devoted to it to be able to treat them in the following years.

1 Sep 2009

Reperfusion therapy proves beneficial for patients with heart attacks

The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half.

1 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Cardiac resynchronization therapy delays the progression of heart failure

A therapy called cardiac resynchronization can significantly delay the progression of heart failure, according to a major international study published in the New England Journal of Medicine.

1 Sep 2009

Daxor's signed trial agreement with Pacific Cardiology to provide the BVA-100 instrument

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Pacific Cardiology, LLC of Honolulu, Hawaii. This will provide Pacific Cardiology with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume.

1 Sep 2009

Low level exposure to carbon dioxide leads to increased risk of hospitalization in older people

Exposure to carbon monoxide, even at levels well below national limits, is associated with an increased risk of hospitalization for the elderly with heart problems, according to a study published today in Circulation: Journal of the American Heart Association.

1 Sep 2009

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.

31 Aug 2009

Geron to present updates on product development programs at four investor conferences in September

Geron Corporation today announced that the company will present updates of its product development programs at four investor conferences in the month of September.

31 Aug 2009

Clinical data of the REVERSE trial reveals how CRT improves functioning of the heart

Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.

30 Aug 2009

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Boston Scientific Corporation today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

28 Aug 2009

NYP/Weill Cornell research reveals that prolonged QRS duration indicates abnormal pumping of the heart

QRS duration (QRSd) is one of several measures of heart function recorded during a routine electrocardiogram (ECG). It is a composite of waves showing the length of time it takes for an electrical signal to get all the way through the pumping chambers of the heart. Prolonged QRSd is a sign of an abnormal electrical system of the heart and is often found when the heart isn't pumping efficiently.

28 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Geron Corporation today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

27 Aug 2009

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.

27 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Heart Failure News and Research

Further Reading

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

Patient enrollment completed for the Berlin Heart EXCOR Pediatric IDE clinical study

First AbioCor Total Replacement Heart recipient does not survive

Telemonitoring systems enable early detection of silent, asymptomatic arrhythmias in heart

Atrial fibrillation ablation - one of the fastest growing cardiology techniques

Reperfusion therapy proves beneficial for patients with heart attacks

Cimzia approved for treating adult patients with rheumatoid arthritis

Cardiac resynchronization therapy delays the progression of heart failure

Daxor's signed trial agreement with Pacific Cardiology to provide the BVA-100 instrument

Low level exposure to carbon dioxide leads to increased risk of hospitalization in older people

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Geron to present updates on product development programs at four investor conferences in September

Clinical data of the REVERSE trial reveals how CRT improves functioning of the heart

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

NYP/Weill Cornell research reveals that prolonged QRS duration indicates abnormal pumping of the heart

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News